

2026 Area of Interest for Pulmonary Hypertension

Pulmonary Hypertension Areas of Interest

Effective January 2026, the Pulmonary Hypertension (PH) Investigator Studies Program (MISP) Review Committee (RC) will accept submissions within our current areas of interest (AOIs). This is a competitive process that will be conducted by the PH MISP RC. Decisions will be made on the basis of scientific merit and strategic fit within the AOIs (which are subject to change).

We kindly request that you carefully review the guidance and adhere to the specified submission dates noted below.

The following areas are of interest to Investigator Studies Program Committee:

Pulmonary Hypertension (Sotatercept)

- Characterizing activin signaling pathways through which sotatercept exerts its biological effects and regulates PH (including Group 1-3).
- Impact of activin signaling inhibition on physiologic/pathophysiologic changes and potential biomarkers in PAH patients.
- Effect of sotatercept in select PAH subgroups (CTD, age, comorbidities, etc./ disease severity/ background therapies).
- Effects of sotatercept in other PH groups (PH-ILD, PH-Sarcoidosis)
- Using real world evidence to study effects of sotatercept in patients with Group 1 PAH.

※国内未承認領域でのご提案に関しては、基礎研究のみ受け付けます。詳しくは別途お問合せください。